Patients with lung cancers responsive to immunotherapy drug beat standard odds of survival Johns Hopkins Medicine – EurekAlert (press release)
|
Patients with lung cancers responsive to immunotherapy drug beat standard odds of survival Johns Hopkins Medicine
EurekAlert (press release) More than seven years after the start of one of the first clinical trials of the immunotherapy drug nivolumab, researchers at the Johns Hopkins Kimmel Cancer Center report that the five-year survival estimate for a limited subset of people with … |
